Dongkook Pharmaceutical Launches Hospital-Exclusive 'Centellian MD Cream' for Protecting Damaged Skin

Centella Asiatica Quantitative Extract Contained
Enhanced Functionality for Skin Protection and Soothing

Centellian MD Cream by Dongkook Pharmaceutical. [Photo by Dongkook Pharmaceutical]

[Asia Economy Reporter Lee Gwan-joo] Dongkook Pharmaceutical announced on the 14th that it will launch the hospital-exclusive medical device cream 'Centellian MD Cream.'

Centellian MD Cream is classified as a Class 2 medical device called 'adhesive transparent wound dressing.' It is a medical device cream used for patients with damaged skin barriers such as dry skin, atopy, and burns. It forms a film on the epidermis to prevent moisture loss, thereby protecting and helping to regenerate the damaged skin barrier.

The cream contains Centella Asiatica quantitatively extracted (TECA), composed of three key ingredients: Madecassic acid, Asiaticoside, and Asiatic acid. According to the company, unlike existing MD creams, it features enhanced functionalities such as skin protection and soothing effects.

It is a preservative-free, colorant-free, and fragrance-free product that minimizes elements that may cause irritation, and its refreshing absorption formula makes it suitable for use from children to adults.

A Dongkook Pharmaceutical official stated, "Centellian MD Cream is a product that embodies over 50 years of technology and know-how in the quantitative extraction of Centella Asiatica, which can help protect patients' damaged skin barriers. Patients prescribed the cream for treatment purposes at hospitals can also claim reimbursement through actual expense insurance, minimizing their financial burden."

This content was produced with the assistance of AI translation services.